Video

CDK4/6 Inhibitors in Metastatic Breast Cancer

For High-Definition, Click

Novel therapies targeting CDK 4/6 have generated considerable excitement as treatments for patients with ER-positive metastatic breast cancer. The combination of the CDK 4/6 inhibitor palbociclib with letrozole demonstrated significantly improved clinical outcomes in the phase II PALOMA-1 trial.

To further explore palbociclib, a phase III trial combining the drug with letrozole was opened in February 2013. In December 2013, the trial had already accrued 25% of the necessary patients, notes Hope S. Rugo, MD. Additionally, a trial is exploring second-line palbociclib with fulvestrant in women with HR-positive metastatic breast cancer.

In addition to palbociclib, a number of other agents are being investigated across several clinical trials. The CDK 4/6 inhibitor LEE011 has demonstrated promising activity in patients with refractory ER-positive breast cancer, notes Denise A. Yardley, MD. In future clinical trials, this agent will be explored in combination with the alpha-specific PI3K inhibitor BYL719.

Adding to the excitement for this class of drugs, CDK 4/6 inhibitors may also be active in HER2-positive breast cancer, suggests Joyce A. O’Shaughnessy, MD. A study is planned that will explore LEE011 in combination with T-DM1 as a treatment for patients with HER2-positive metastatic breast cancer, O’Shaughnessy notes.

Related Videos
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Cedric Pobel, MD
Ruth M. O’Regan, MD
Peter Forsyth, MD
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.